WALTHAM, Mass., Feb. 8 /PRNewswire/ -- ImmuLogic Pharmaceutical
Corporation (Nasdaq: IMUL) announced today that its Board of Directors has
decided to conclude the business activities of the Company as soon as
practicable. The management and the Board of Directors of the Company are
currently preparing a plan designed to maximize distributions of the Company's
assets to its stockholders. The Company expects that implementation of this
plan will require stockholder approval and currently anticipates providing
details regarding the plan during the first quarter of 1999.
ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company
located in Waltham, Massachusetts. The Company's press releases are available
through Company News on Call by fax at 800-758-5804, ext. 114501, and on the
Internet at http://www.prnewswire.com.
This press release contains forward-looking statements that involve a
number of risks and uncertainties, including risks and uncertainties that
relate to restructuring of the Company's business, assets or liabilities, and
the other risk factors detailed in the Company's Annual Report on Form 10-K
for the year ended December 31, 1997.
SOURCE ImmuLogic Pharmaceutical Corporation
 back to top
Company News On-Call:
http://www.prnewswire.com/comp/114501.html or fax,
800-758-5804, ext. 114501
CONTACT:
Investor Relations of ImmuLogic
Pharmaceutical Corporation, 781-466-6000
|
